Temozolomide in malignant gliomas: Current use and future targets

J. Lee Villano; Tara E. Seery; Linda R. Bressler

doi:10.1007/s00280-009-1050-5

Temozolomide in malignant gliomas: Current use and future targets

J. Lee Villano, Tara E. Seery, Linda R. Bressler

Research output: Contribution to journal › Short survey › peer-review

165 Scopus citations

Abstract

Temozolomide (TMZ) is an oral alkylating agent that is regarded as a tolerable and effective drug. When combined with radiotherapy in patients with newly diagnosed glioblastoma, survival is significantly prolonged. This finding has led to widespread use of TMZ for patients with this disease. We summarize developing concerns regarding the use of TMZ, imaging of malignant gliomas, and the pharmacology of TMZ-mechanism of action, scheduling and strategies for overcoming resistance.

Original language	English
Pages (from-to)	647-655
Number of pages	9
Journal	Cancer Chemotherapy and Pharmacology
Volume	64
Issue number	4
DOIs	https://doi.org/10.1007/s00280-009-1050-5
State	Published - Sep 2009

Keywords

Alkylating chemotherapy
Brain tumor
Glioblastoma
Malignant glioma
Temozolomide
Tumor resistance

ASJC Scopus subject areas

Oncology
Toxicology
Pharmacology
Cancer Research
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00280-009-1050-5

Cite this

@article{d9cd8724337c470687325771656bf092,

title = "Temozolomide in malignant gliomas: Current use and future targets",

abstract = "Temozolomide (TMZ) is an oral alkylating agent that is regarded as a tolerable and effective drug. When combined with radiotherapy in patients with newly diagnosed glioblastoma, survival is significantly prolonged. This finding has led to widespread use of TMZ for patients with this disease. We summarize developing concerns regarding the use of TMZ, imaging of malignant gliomas, and the pharmacology of TMZ-mechanism of action, scheduling and strategies for overcoming resistance.",

keywords = "Alkylating chemotherapy, Brain tumor, Glioblastoma, Malignant glioma, Temozolomide, Tumor resistance",

author = "Villano, {J. Lee} and Seery, {Tara E.} and Bressler, {Linda R.}",

year = "2009",

month = sep,

doi = "10.1007/s00280-009-1050-5",

language = "English",

volume = "64",

pages = "647--655",

number = "4",

}

TY - JOUR

T1 - Temozolomide in malignant gliomas

T2 - Current use and future targets

AU - Villano, J. Lee

AU - Seery, Tara E.

AU - Bressler, Linda R.

PY - 2009/9

Y1 - 2009/9

N2 - Temozolomide (TMZ) is an oral alkylating agent that is regarded as a tolerable and effective drug. When combined with radiotherapy in patients with newly diagnosed glioblastoma, survival is significantly prolonged. This finding has led to widespread use of TMZ for patients with this disease. We summarize developing concerns regarding the use of TMZ, imaging of malignant gliomas, and the pharmacology of TMZ-mechanism of action, scheduling and strategies for overcoming resistance.

AB - Temozolomide (TMZ) is an oral alkylating agent that is regarded as a tolerable and effective drug. When combined with radiotherapy in patients with newly diagnosed glioblastoma, survival is significantly prolonged. This finding has led to widespread use of TMZ for patients with this disease. We summarize developing concerns regarding the use of TMZ, imaging of malignant gliomas, and the pharmacology of TMZ-mechanism of action, scheduling and strategies for overcoming resistance.

KW - Alkylating chemotherapy

KW - Brain tumor

KW - Glioblastoma

KW - Malignant glioma

KW - Temozolomide

KW - Tumor resistance

UR - http://www.scopus.com/inward/record.url?scp=68149157509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68149157509&partnerID=8YFLogxK

U2 - 10.1007/s00280-009-1050-5

DO - 10.1007/s00280-009-1050-5

M3 - Short survey

C2 - 19543728

AN - SCOPUS:68149157509

SN - 0344-5704

VL - 64

SP - 647

EP - 655

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 4

ER -

Temozolomide in malignant gliomas: Current use and future targets

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this